Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Jeremy S. Myers"'
Autor:
Wenyan Zhong, Jeremy S. Myers, Fang Wang, Kai Wang, Justin Lucas, Edward Rosfjord, Judy Lucas, Andrea T. Hooper, Sharon Yang, Lu Anna Lemon, Magali Guffroy, Chad May, Jadwiga R. Bienkowska, Paul A. Rejto
Publikováno v:
BMC Genomics, Vol 21, Iss 1, Pp 1-17 (2020)
Abstract Background The clinical success of immune checkpoint inhibitors demonstrates that reactivation of the human immune system delivers durable responses for some patients and represents an exciting approach for cancer treatment. An important cla
Externí odkaz:
https://doaj.org/article/8611614a41274bc88abf31f1a71b7264
Autor:
Jay S Fine, Louis Matis, Stella Martomo, Xingyue An, Mohosin Sarkar, Abudukadier Abulizi, Guixian Jin, Evelyn Teran, Danielle Klaskin, Maria Hackett, Hayden Karp, Julio Rodriguez, Sonali Dhindwal, Changqing Yuan, Zengzu Lai, Jennifer Zeiger, Amber Fearnley, Oksana A Sergeeva, Eric M Tam, Tracy Lichter, Jeremy S Myers
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/26c6651b0b594272bbdce220e09fc635
Autor:
Hans-Peter Gerber, Kim T. Arndt, Christopher J. O'Donnell, Andreas Maderna, Edmund Graziani, Judy Lucas, Mike Cinque, Kenny Sung Kyoo Kim, Kiran Khandke, Manoj B. Charati, William Hu, My-Hanh Lam, Sylvia Musto, Maximillian T. Follettie, Veronica Diesl, Fang Wang, Eugene Melamud, Jeremy S. Myers, Guixian Jin, Matthew Sung, Xingzhi Tan, Frank Loganzo
Supplementary Figures S1 to S11. Supplementary Figure S1: Schematic illustration of the approach used to create trastuzumab-maytansinoid ADC resistant cell lines. Supplementary Figure S2: Structures of payloads and ADCs. Supplementary Figure S3: 361-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d79603999d612f532f7eea3bb1f02469
https://doi.org/10.1158/1535-7163.22500637.v1
https://doi.org/10.1158/1535-7163.22500637.v1
Autor:
Hans-Peter Gerber, Kim T. Arndt, Christopher J. O'Donnell, Andreas Maderna, Edmund Graziani, Judy Lucas, Mike Cinque, Kenny Sung Kyoo Kim, Kiran Khandke, Manoj B. Charati, William Hu, My-Hanh Lam, Sylvia Musto, Maximillian T. Follettie, Veronica Diesl, Fang Wang, Eugene Melamud, Jeremy S. Myers, Guixian Jin, Matthew Sung, Xingzhi Tan, Frank Loganzo
Supplementary Methods, Table S1 S2, and Figure Legends. Supplementary Table S1: Properties of cell lines made resistant to TM-conjugate. Supplementary Table S2: Relative resistance of selected free payloads and Cys-capped-released species in H69 (no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030c02d31cd9136288d63c1ed31908a5
https://doi.org/10.1158/1535-7163.22500634.v1
https://doi.org/10.1158/1535-7163.22500634.v1
Autor:
Frank Loganzo, Hans-Peter Gerber, Judy Lucas, Edward Rosfjord, Jeremy S. Myers, Russell Dushin, Dahui Zhou, Lindsay King, Laurie Tylaska, Fang Wang, Christine Hosselet, Jonathan Golas, Bingwen Lu, Xingzhi Tan, Matthew Sung
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate (ADC) that has demonstrated clinical benefit for patients with HER2+ metastatic breast cancer; however, its clinical activity is limited by inherent or acquired drug resistance. The molecu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98b7849b4a80f721f9c5c51b80a5df70
https://doi.org/10.1158/1535-7163.c.6537949.v1
https://doi.org/10.1158/1535-7163.c.6537949.v1
Autor:
Frank Loganzo, Hans-Peter Gerber, Judy Lucas, Edward Rosfjord, Jeremy S. Myers, Russell Dushin, Dahui Zhou, Lindsay King, Laurie Tylaska, Fang Wang, Christine Hosselet, Jonathan Golas, Bingwen Lu, Xingzhi Tan, Matthew Sung
Supplementary Figure S1: N87 and N87-TM cells are similarly sensitive to unconjugated DM1-SMe; Supplementary Figure S2: Trastuzumab binding to N87 and N87-TM cells; Supplementary Figure S3: Generation and characterization of T-DM1-resistant HCC1954-T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70985131e8e817af104564e8da06ea1d
https://doi.org/10.1158/1535-7163.22505098.v1
https://doi.org/10.1158/1535-7163.22505098.v1
Autor:
Mohosin Sarkar, Eric M. Tam, Guixian Jin, Shu Shien Chin, Abudukadier Abulizi, Oksana A. Sergeeva, Zengzu Lai, Evelyn Teran, Hayden Karp, Danielle Klaskin, Nana Adjoa Pels, Xingyue An, Jennifer Ziegler, Changqing Yuan, Maria Hackettt, Sonali Dhindwal, Amber Fearnley, Julio Rodriguez, Louis Matis, Jay S. Fine, Jeremy S. Myers
Publikováno v:
Cancer Research. 83:2971-2971
Bispecific antibodies which bind a tumor antigen and the CD3 heterodimer of the T cell receptor to form a synthetic immunological synapse represent a class of T cell engagers that has been clinically validated with the approvals of blinatumomab (Blin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::119b5ba4e68877cfdbd7d30211801e41
https://doi.org/10.1158/1538-7445.am2023-2971
https://doi.org/10.1158/1538-7445.am2023-2971
Autor:
Mandy Shu Shien Chin, Mohosin Sarkar, Eric Tam, Abudukadier Abulizi, Guixian Jin, Xingyue An, Evelyn Teran, Danielle M Klaskin, Nana Adjoa Pels, Maria Hackett, Oksana A Sergeeva, Hayden Karp, Julio Rodriguez, Sonali Dhindwal, Changqing Yuan, Zengzu Lai, Jennifer Zeiger, Amber Fearnley, Louis Matis, Jay Fine, Jeremy S Myers
Publikováno v:
Cancer Immunology Research. 10:B44-B44
CD3-bispecifics are antibody-based therapies that can simultaneously bind to a tumor cell surface antigen and T cells to establish a synapse between the tumor and T cell and activate T cell to induce specific killing of the tumor cell. CD3-bispecific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffdb9fd3c97af6471b6ac631bc53398d
https://doi.org/10.1158/2326-6074.tumimm22-b44
https://doi.org/10.1158/2326-6074.tumimm22-b44
Autor:
Xiaoran S. Yang, Michael D. Arensman, Mary Mileski, Fang Wang, Christina H. Eng, Jeremy S. Myers, Robert T. Abraham, Danielle Leahy, Lourdes Toral-Barza, Shibing Deng, Edward Rosfjord
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance xCT, the cystine–glutamate antiporter, has been implicated in supporting both tumor growth and T cell proliferation; thus, antitumor effects of systemic xCT inhibition may be blunted by compromised antitumor immunity. This report detai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33dbe7ee0e6b5a6ef16144037f68c55b
http://europepmc.org/articles/PMC6511047
http://europepmc.org/articles/PMC6511047
Autor:
Maximillian T. Follettie, David Fruhling, Joy Grant, James Ahn, Jeremy S. Myers, Wenyan Zhong, Benedikt Bosbach, Jadwiga Bienkowska, Kim Arndt, Brendan Veeneman, Ying Gao
Publikováno v:
Nucleic Acids Research
CRISPR/Cas9 functional genomic screens have emerged as essential tools in drug target discovery. However, the sensitivity of available genome-wide CRISPR libraries is impaired by guides which inefficiently abrogate gene function. While Cas9 cleavage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba346670bdaa286b5854bdd14d963590
https://pubmed.ncbi.nlm.nih.gov/32821942
https://pubmed.ncbi.nlm.nih.gov/32821942